Clinical trial of a new immunosuppresive agent to treat new onset Type 1 diabetes mellitus
Physicians at Columbia University are studying the ability of a new investigational drug to prevent or even reverse the destruction of insulin producing cells in patients with new onset Type 1 diabetes. The agent they are studying is an immune suppressive but differs in action from those previously studied in patients with Type 1 diabetes. In animal models of Type 1 diabetes, the drug has reversed the disease and prevented its recurrence. In patients with diabetes, who have been treated with the drug, the results have been encouraging.
The study is available to patients with Type 1 diabetes within 6 weeks of diagnosis between the ages of 8 and 35. The treatment protocol will be carried out at the Presbyterian Hospital of Columbia University in New York. The trial is supported by the Juvenile Diabetes Foundation Int., and the National Institutes of Health.
As of February 27, 2000, the study has enough participants for the next three to four weeks.
Original posting April 3, 1999
Updated February 27, 2000
Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2016. Comments and Feedback.